What is HC Wainwright’s Forecast for Zymeworks Q3 Earnings?

Zymeworks Inc. (NYSE:ZYME) – HC Wainwright issued their Q3 2025 EPS estimates for shares of Zymeworks in a note issued to investors on Tuesday, October 14th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($0.48) for the quarter. HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.26) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.02) EPS.

Several other research firms have also weighed in on ZYME. Citigroup lifted their price objective on shares of Zymeworks from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, August 11th. B. Riley began coverage on shares of Zymeworks in a research note on Friday, October 10th. They issued a “buy” rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Zymeworks has an average rating of “Buy” and an average target price of $24.13.

Zymeworks Price Performance

NYSE:ZYME opened at $18.62 on Thursday. Zymeworks has a one year low of $9.03 and a one year high of $19.50. The firm’s 50 day simple moving average is $15.50 and its 200 day simple moving average is $13.38. The company has a market cap of $1.40 billion, a PE ratio of -12.41 and a beta of 1.51.

Zymeworks (NYSE:ZYME) last posted its earnings results on Thursday, August 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.55. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business had revenue of $48.73 million for the quarter, compared to the consensus estimate of $17.18 million. During the same period last year, the company earned ($0.49) EPS. The firm’s revenue was up 153.2% compared to the same quarter last year.

Hedge Funds Weigh In On Zymeworks

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. boosted its holdings in shares of Zymeworks by 169.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,326,774 shares of the company’s stock worth $22,661,000 after buying an additional 833,994 shares during the last quarter. Squarepoint Ops LLC raised its stake in Zymeworks by 144.6% in the 2nd quarter. Squarepoint Ops LLC now owns 155,599 shares of the company’s stock valued at $1,953,000 after acquiring an additional 91,997 shares during the period. Tower Research Capital LLC TRC raised its stake in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after acquiring an additional 1,131 shares during the period. Vestal Point Capital LP raised its stake in Zymeworks by 130.0% in the 2nd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $14,432,000 after acquiring an additional 650,000 shares during the period. Finally, Rubric Capital Management LP raised its stake in Zymeworks by 8.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,710,551 shares of the company’s stock valued at $59,117,000 after acquiring an additional 372,107 shares during the period. 92.89% of the stock is owned by hedge funds and other institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.